原始来源记录

lebrikizumab · NCT06280716 注册更新

状态: ACTIVE_NOT_RECRUITING → COMPLETED; 完成时间: 2026-08 → 2026-07-16; 主要结局: ['Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) (≥75% Reduction in EASI Score) for Mono Cohort', 'Percentage of Participants Achieving EASI-75 for Combo Cohort', 'Percentage of Participants Achieving IGA Score of 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 for Mono Cohort', 'Percentage of Participants Achieving IGA Score of 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 for Combo Cohort'] → ['第 16 周达到湿疹面积和严重程度指数 (EASI)-75（从基线 EASI 评分降低 ≥75%）的参与者百分比（联合队列：安慰剂 + TCS 与 250 mg 度利珠单抗 + TCS；单一治疗队列：安慰剂与 250 mg 度利珠单抗）']